Chemoimmunotherapy of melanoma. Is it time for phase III trials?

Cancer. 1995 Feb 15;75(4):905-7. doi: 10.1002/1097-0142(19950215)75:4<905::aid-cncr2820750402>3.0.co;2-a.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Clinical Trials, Phase III as Topic
  • Combined Modality Therapy
  • Dacarbazine / therapeutic use*
  • Humans
  • Immunotherapy
  • Interleukin-2 / therapeutic use*
  • Melanoma / therapy*

Substances

  • Interleukin-2
  • Dacarbazine